Patent · US Active

Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer

US10077261B2 · kind B2 · utility

7Cited by

0References

16Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Peter J. Connolly · New Providence, US
Gilles Bignan · Bound Brook, US
Tianbao Lu · Collegeville, US
Michael H. Parker · Doylestown, US
Donald Ludovici · Quakertown, US
Christophe Meyer · Oissel, FR
Lieven Meerpoel · Beerse, BE
Karine Smans · Beerse, BE
Christian Rocaboy · Murcia, ES

Key dates

Filing date	Sep 11, 2015
Grant date	Sep 18, 2018
Priority date	—
Expiry date	Sep 11, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.